A special discovery master appointed in the Zoloft multidistrict litigation has recommended that the Pfizer Inc. need not provide information about its internal communications about plaintiffs’ doctors just yet.
Special discovery master Andrew Chirls of Fineman, Krekstein & Harris in Philadelphia, said Pfizer’s internal communications about plaintiffs’ doctors “may be helpful in the selection of cases, and it may even be more helpful in developing proof about Pfizer’s marketing methods, which the PSC has argued is relevant under the law of at least some states. But it is not what was agreed upon as the DFS [defendants' fact sheet] was negotiated, and discovery of this material in a later phase is not foreclosed.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
